UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): January 13, 2025 |
VIRACTA THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | 000-51531 | 94-3295878 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
2533 S. Coast Hwy. 101, Suite 210 | |
Cardiff, California | | 92007 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (858) 400-8470 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share | | VIRX | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the previously disclosed resignation of Barry J. Simon, M.D. from the Company’s board of directors (the “Board”) and audit committee on December 18, 2024, the Company was no longer in compliance with Nasdaq’s audit committee requirements under Nasdaq Listing Rule 5605(c)(2). In accordance with Nasdaq Listing Rule 5605(c)(4), the Company has been provided a cure period to regain compliance. The cure period allows the Company to remedy the deficiency by the earlier of (i) its next annual shareholders’ meeting or (ii) December 18, 2025. If the next annual shareholders’ meeting is held before June 16, 2025, the Company must provide evidence of compliance no later than June 16, 2025.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | | Viracta Therapeutics, Inc. |
| | | |
Date: | January 17, 2025 | By: | /s/ Michael Faerm |
| | | Michael Faerm
Chief Financial Officer |
